NCT01498328

A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma (ReACT)

Conditions: Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma, Glioblastoma With Oligodendroglial Component
Sponsors: Celldex Therapeutics
Phase II

NCT01480479

Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma (ACT IV)

Conditions: Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma, Glioblastoma With Oligodendroglial Component
Sponsors: Celldex Therapeutics
Phase III

NCT01250470

Survivin Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma

Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH (SurVaxM) in Patients with Survivin-Positive Malignant Gliomas

Conditions: Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Recurrent Adult Brain Tumor
Sponsors: Roswell Park Cancer Institute
Collaborators: NCI, MimiVax
Phase I

NCT01189383

IL15 Dendritic Cell Vaccine for Patients With Resected Stage IIIc and Stage IV Melanoma

Conditions: Stage IIIc/IV Melanoma
Sponsors: Baylor Research Institute
Phase I, II

NCT01174082

Donor Lymphocyte Infusion for Myeloma

Conditions: Myeloma
Sponsors: M.D. Anderson Cancer Center
Phase 2

NCT00643097

Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Conditions: Brain and Central Nervous System Tumors
Sponsors: Duke University, National Institute of Neurological Disorders and Stroke
Phase II

NCT00621036

Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma

Conditions: Brain and Central Nervous System Tumors, Lymphoma, Lymphoproliferative Disorder, Small Intestine Cancer
Sponsors: Simmons Cancer Center
Phase II

NCT00574886

Idiotype Vaccine Following High-Dose Chemotherapy and Hematopoietic Stem Cell Transplantation for Patients With Lymphoma Who Had Failed Induction Chemotherapy

Conditions: Lymphoma
Sponsors: University of Nebraska
Phase n/a 

NCT00530140

Idiotypic Vaccination for Follicular Lymphoma Patients

Conditions: Follicular Lymphoma, First Relapse/Progression
Sponsors: Instituto Cientifico y Tecnologico de Navarra, Universidad de Navarra
Phase II

NCT00510471

Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma

Conditions: Non-Hodgkin's Lymphoma
Sponsors: Genitope Corporation
Phase II